JFJordan FeldMD, MPHSlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017HBV therapy & Approaches to Cure- Jordan Feld, MD, MPHView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_11: HIV-1-infected Males and Females under Less-Drug Regimens Achieve Antiretroviral Levels above the Inhibitory Concentration in the Genital Tract.- Sandrine LefeuvreView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_10: Pharmacokinetics of Dolutegravir and Rilpivirine after Switching to the Two-Drug Regimen from an Efavirenz- or Nevirapine-Based Antiretroviral Regimen: SWORD-1/2 Pooled PK Analysis- Kimberly Adkison, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_7: A Comparison of the Pharmacokinetics of Dolutegravir during Pregnancy and Postpartum- Dr Pauline BollenView Slideset
MBMarta BoffitoMD, PhD, FRCP, MBASlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_8: Relationship between dolutegravir plasma exposure, quality of sleep and its functional outcome in patients living with HIV over the age of 60 years.- Marta Boffito, MD, PhD, FRCPView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017Clinical Aspects of Pediatric Treatment- Tim Cressey, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017Current Challenges in Pediatric Drug Development- Robert Ward, MD, FAAP, FCPView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_6: Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir- Catia Marzolini, PharmD, PhDView Slideset
JMJosé MoltóMD, PhDSlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_3: Pharmacokinetics of darunavir/cobicistat and etravirine alone and coadministered in HIV-infected patients- José Moltó, MD, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_5: Confirmation of the drug-drug interaction (DDI) potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives- Dr Sophia MajeedView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_4: Evaluation of the Drug-Drug Interaction Potential between Cobicistat-Boosted Protease Inhibitors and Statins - Dr Joseph CustodioView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_2: Effects of cobicistat on tenofovir durability: is it time to rethink at TAF trials?- Dario Cattaneo, PharmD, PhDView Slideset
